Pelage Pharmaceuticals

Woman experiencing hair loss
#Alopecia #Hair loss #Pelage Pharmaceuticals #Phase II trial

‘Molecular switch’ could reverse the effects of alopecia

A Phase IIa clinical trial has begun evaluating the safety and efficacy of Pelage Pharmaceuticals’ PP405, a novel topical small molecule, for the treatment of androgenetic alopecia (pattern baldness). The company is enrolling 60 women and men for the clinical study. PP405 is designed to reactivate… Read More

#Editor's Choice #News